Indeed, our results suggest that ILK can be a particularly interesting target to evaluate for the treatment of intestinal pathologies such as colon cancer and inflammatory bowel diseases since deregulation of fibronectin, integrin α5β1 and RhoA function or expression have been shown to contribute to the progression of colon cancer and poor prognosis [82–84], while abnormal assembly of FN can trigger intestinal tumor invasion [85] and excessive collagen deposition associated with the formation of fibrous lesions and tissues fibrosis in inflammatory condition [86, 87]. The gene discussed is RHOA; the disease is intestinal neoplasm.